• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates.

作者信息

Noya F J, Rench M A, Courtney J T, Feldman S, Baker C J

机构信息

Section of Infectious Diseases, Baylor College of Medicine, Houston, TX 77030.

出版信息

Pediatr Infect Dis J. 1989 Nov;8(11):759-63. doi: 10.1097/00006454-198911000-00006.

DOI:10.1097/00006454-198911000-00006
PMID:2480576
Abstract

We studied the pharmacokinetics of single doses of intravenous immunoglobulin (IVIG) of 1000, 750 and 500 mg/kg administered to 21 neonates with birth weights from 750 to 1500 g. No adverse effects were detected. Mean pharmacokinetic values for the large, intermediate and small dose groups, respectively, were: elimination half-life, 19.6, 28.7 and 22.1 days; clearance, 5.2, 5.6 and 3.7 ml/kg/day; volume of distribution, 151, 255 and 130 ml/kg. Mean peak IgG concentrations in serum were 1826, 1476 and 1257 mg/dl for the large, intermediate and small dose groups, respectively. Mean IgG on post-infusion Days 1 to 28 were similar for the intermediate and small dose groups but were higher in the larger dose group. Both large and intermediate doses achieved larger increases in IgG over preinfusion values (delta IgG) than the small dose. The differences in delta IgG between the large and intermediate doses were less notable. The wide variability observed indicates that individualization of intravenous immunoglobulin dosage will be required in these patients.

摘要

相似文献

1
Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates.
Pediatr Infect Dis J. 1989 Nov;8(11):759-63. doi: 10.1097/00006454-198911000-00006.
2
Disposition of an immunoglobulin intravenous preparation in very low birth weight neonates.极低出生体重新生儿静脉注射免疫球蛋白制剂的处置情况。
J Pediatr. 1988 Feb;112(2):278-83. doi: 10.1016/s0022-3476(88)80070-2.
3
Prophylactic intravenous administration of immune globulin in preterm infants: effect on serum immunoglobulin concentrations during the first year of life.早产儿预防性静脉注射免疫球蛋白:对生命第一年血清免疫球蛋白浓度的影响。
J Pediatr. 1991 Oct;119(4):624-9. doi: 10.1016/s0022-3476(05)82417-5.
4
Immunoglobulin subclass concentration in preterm infants treated prophylactically with different intravenous immunoglobins.接受不同静脉注射免疫球蛋白预防性治疗的早产儿的免疫球蛋白亚类浓度。
Am J Perinatol. 1995 Sep;12(5):306-9. doi: 10.1055/s-2007-994481.
5
[Intravenous immunoglobulins in newborn infants at risk of infection. Comparative efficacy of preparations 7S and 5S].[处于感染风险的新生儿静脉注射免疫球蛋白。7S和5S制剂的比较疗效]
Minerva Pediatr. 1990 Jan-Feb;42(1-2):15-8.
6
A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.单次静脉输注丙种球蛋白与四次输注丙种球蛋白治疗急性川崎综合征的比较。
N Engl J Med. 1991 Jun 6;324(23):1633-9. doi: 10.1056/NEJM199106063242305.
7
[A case of idiopathic thrombocytopenic purpura responding to high-dose globulin therapy following platelet transfusion with globulin therapy].
Rinsho Ketsueki. 1987 Oct;28(10):1872-5.
8
Alterations in the half-life and clearance of IgG during therapy with intravenous gamma-globulin in 16 patients with severe primary humoral immunodeficiency.16例严重原发性体液免疫缺陷患者静脉注射丙种球蛋白治疗期间IgG半衰期和清除率的变化
J Clin Immunol. 1986 May;6(3):256-64. doi: 10.1007/BF00918706.
9
Pharmacokinetics of intravenous immunoglobulin in neonates.新生儿静脉注射免疫球蛋白的药代动力学
Vox Sang. 1989;57(4):243-8. doi: 10.1111/j.1423-0410.1989.tb00836.x.
10
[Indications for high-dose immunoglobulin therapy in idiopathic thrombocytopenic purpura and its evaluation].
Rinsho Ketsueki. 1986 Sep;27(9):1712-20.

引用本文的文献

1
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics.原发性免疫缺陷病的免疫球蛋白治疗(第 1 部分):了解药代动力学。
Immunotherapy. 2024;16(13):879-894. doi: 10.1080/1750743X.2024.2382081. Epub 2024 Sep 26.
2
Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence.基于药代动力学证据优化免疫球蛋白剂量的考量
Antibodies (Basel). 2020 Jun 19;9(2):24. doi: 10.3390/antib9020024.
3
Effectiveness of Immunoglobulins for the Prevention of Systemic Infections : A Meta-Analysis of 8 Clinical Studies in Premature Infants.
免疫球蛋白预防全身感染的有效性:对8项早产儿临床研究的荟萃分析
Clin Drug Investig. 1995 Dec;10(6):328-36. doi: 10.2165/00044011-199510060-00003.
4
Pharmacokinetic modeling of therapies for systemic lupus erythematosus.系统性红斑狼疮治疗的药代动力学建模
Expert Rev Clin Pharmacol. 2015;8(5):587-603. doi: 10.1586/17512433.2015.1059751. Epub 2015 Jul 9.